Cohort characteristics at entry and comorbidities over study follow-up (n=1 000 764)
| Cohort characteristics | Without cancer (N (%)) | Cancer* (N (%)) | Total (N (%)) |
| Age group at baseline (years) | |||
| 15–24 | 311 087 (32.0%) | 1747 (5.9%) | 312 834 (31.3%) |
| 25–34 | 255 477 (26.3%) | 4431 (15.0%) | 259 908 (26.0%) |
| 35–44 | 214 955 (22.1%) | 6997 (23.8%) | 221 952 (22.2%) |
| 45–54 | 101 959 (10.5%) | 5402 (18.3%) | 107 361 (10.7%) |
| 55–64 | 50 987 (5.2%) | 5235 (17.8%) | 56 222 (5.6%) |
| 65–74 | 27 322 (2.8%) | 4148 (14.1%) | 31 470 (3.1%) |
| 75–84 | 8051 (0.8%) | 1336 (4.5%) | 9387 (0.9%) |
| 85–94 | 1408 (0.1%) | 148 (0.5%) | 1556 (0.2%) |
| ≥95 | 70 (0.0%) | 4 (0.0%) | 74 (0.0%) |
| Gender | |||
| Female | 497 883 (51.3%) | 17 418 (59.1%) | 515 301 (51.5%) |
| Male | 473 433 (48.7%) | 12 030 (40.9%) | 485 463 (48.5%) |
| TB incidence by country of origin (per 100 000 population) | |||
| 0–30 | 158 280 (16.3%) | 5425 (18.4%) | 163 705 (16.4%) |
| 31–100 | 250 830 (25.8%) | 6018 (20.4%) | 256 848 (25.7%) |
| 101–200 | 310 359 (32.0%) | 10 474 (35.6%) | 320 833 (32.1%) |
| >200 | 251 821 (25.9%) | 7531 (25.6%) | 259 352 (25.9%) |
| WHO region | |||
| Western Pacific | 532 415 (54.8%) | 15 981 (54.3%) | 548 396 (54.8%) |
| South-East Asia | 141 507 (14.6%) | 3483 (11.8%) | 144 990 (14.5%) |
| Europe | 126 952 (13.1%) | 5054 (17.2%) | 132 006 (13.2%) |
| Eastern Mediterranean | 75 265 (7.7%) | 1674 (5.7%) | 76 939 (7.7%) |
| Americas | 67 583 (7.0%) | 2303 (7.8%) | 69 886 (7.0%) |
| Africa | 27 242 (2.8%) | 935 (3.2%) | 28 177 (2.8%) |
| Immigration classification | |||
| Refugee | 76 919 (7.9%) | 2039 (6.9%) | 78 958 (7.9%) |
| Family | 321 328 (33.1%) | 14 759 (50.1%) | 336 087 (33.6%) |
| Economic | 573 069 (59.0%) | 12 650 (43.0%) | 585 719 (58.5%) |
| Years in BC | |||
| 0–5 | 800 518 (82.4%) | 22 769 (77.3%) | 823 287 (82.3%) |
| >5 | 170 798 (17.6%) | 6679 (22.7%) | 177 477 (17.7%) |
| Active TB contact | 5676 (0.6%) | 248 (0.8%) | 5924 (0.6%) |
| Comorbidities† | |||
| HIV | 1460 (0.2%) | 109 (0.4%) | 1569 (0.2%) |
| Dialysis-dependent end-stage kidney disease | 1671 (0.2%) | 255 (0.9%) | 1926 (0.2%) |
| Immune-suppression‡ | 22 715 (2.3%) | 2914 (9.9%) | 25 629 (2.6%) |
| Diabetes | 98 519 (10.1%) | 7025 (23.9%) | 105 544 (10.5%) |
| Total | 971 316 (100.0%) | 29 448 (100.0%) | 1 000 764 (100.0%) |
Missing data (country of origin, n=26, WHO region n=370).
*Includes incident cases only.
†Includes incident and prevalent cases.
‡Immune-suppression=includes treatment with immune-suppressing drugs (tumour necrosis factor-α inhibitors, disease-modifying antirheumatic drugs or high-dose steroids or post-transplant).
BC, British Columbia; TB, tuberculosis.